Cynata Therapeutics' Ross Macdonald, PhD, discusses the company's pipeline and clinical-phase trials.
Stem cells have been a hot-button topic for some time now, the subject of quite a bit of hype and controversy, as well. As the dust continues to settle, it has become very clear that specifically mesenchymal stem cells represent a very promising therapeutic modality for diseases that are currently considered untreatable.
Cynata Therapeutics has developed a novel manufacturing platform, called Cymerus, that utilizes mesenchymoangioblasts derived from induced pluripotent stem cells to both economically and efficiently produce therapeutic mesenchymal stem cells that are of consistent quality.
The biotechnology company is pursuing the investigation of mesenchymal stem cell-based therapeutics in several indications, including osteoarthritis, critical limb ischemia, graft-versus-host disease, and acute respiratory distress syndrome, among others.
GeneTherapyLive sat down with Cynata's managing director and chief executive officer Ross Macdonald, PhD, to learn more about the company's clinical pipeline.